Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023

MARAVAI LIFESCIENCES HOLDINGS, INC.

Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.
Martin expected to become CEO on July 27, 2023, per settlement with Danaher entities.
Settlement limits Martin's responsibilities and bars involvement in Nucleic Acid Production segment until July 26, 2023.
Carl Hull continues as Executive Chairman and interim CEO; lawsuit voluntarily dismissed.
Christine Dolan remains COO of Biologics Safety Testing segment, reporting to Martin.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William "Trey" Martin, III

Chief Executive Officer

MRVI · MARAVAI LIFESCIENCES HOLDINGS, INC.

Effective: 2023-07-27
Successor: William "Trey" Martin, III
Filed: December 1, 2022, 6:59 PM ET

its expectation that Martin will assume the role of Chief Executive Officer of the Company effective July 27, 2023

Appointed

William "Trey" Martin, III

President of Biologics Safety Testing Segment

MRVI · MARAVAI LIFESCIENCES HOLDINGS, INC.

Effective: 2022-12-05
Filed: December 1, 2022, 6:59 PM ET

William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment beginning December 5, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William "Trey" Martin, III changed role as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

Action: assume the role of
Role: Chief Executive Officer

Exact text from the filing

its expectation that Martin will assume the role of Chief Executive Officer of the Company effective July 27, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William "Trey" Martin, III was appointed as President of Biologics Safety Testing Segment at MARAVAI LIFESCIENCES HOLDINGS, INC..

Action: to serve as
Role: President of Biologics Safety Testing Segment

Exact text from the filing

William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment beginning December 5, 2022

View on SEC.gov

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-296553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.